Pembro-话题@MedSci

#Pembro#

98篇内容 | 2717人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1787006, encodeId=77c51e8700631, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定, objectType=article, longId=188519, objectId=cccf188519dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cccf188519dd, replyNumber=0, likeNumber=80, createdTime=2020-04-22, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cccf188519dd, moduleTitle=PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cccf188519dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787003, encodeId=32fc1e8700322, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Hyleukin-7（NT-I7）联合Pembrolizumab治疗复发难治晚期实体瘤：美国FDA已批准IND申请, objectType=article, longId=186916, objectId=68271869169f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68271869169f, replyNumber=0, likeNumber=79, createdTime=2020-03-08, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68271869169f, moduleTitle=Hyleukin-7（NT-I7）联合Pembrolizumab治疗复发难治晚期实体瘤：美国FDA已批准IND申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68271869169f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787000, encodeId=b6801e87000f9, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, objectType=article, longId=183247, objectId=74bf18324ece, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74bf18324ece, replyNumber=0, likeNumber=71, createdTime=2020-10-16, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74bf18324ece, moduleTitle=JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74bf18324ece)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787005, encodeId=0e8a1e870057c, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=ASCO：真实世界中pembrolizumab单抗对NSCLC效果如何联用？, objectType=article, longId=187826, objectId=b24018e826cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b24018e826cb, replyNumber=0, likeNumber=76, createdTime=2020-05-10, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b24018e826cb, moduleTitle=ASCO：真实世界中pembrolizumab单抗对NSCLC效果如何联用？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b24018e826cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786999, encodeId=626b1e86999cf, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Lancet：Pembrolizumab治疗复发或转移性头颈部鳞状细胞癌, objectType=article, longId=182385, objectId=dc141823856a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc141823856a, replyNumber=0, likeNumber=82, createdTime=2019-11-25, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc141823856a, moduleTitle=Lancet：Pembrolizumab治疗复发或转移性头颈部鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc141823856a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787004, encodeId=a12c1e8700444, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, objectType=article, longId=187720, objectId=ddb118e72078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb118e72078, replyNumber=0, likeNumber=135, createdTime=2021-01-11, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb118e72078, moduleTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb118e72078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787002, encodeId=19fd1e8700220, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, objectType=article, longId=184092, objectId=92cd1840921e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cd1840921e, replyNumber=0, likeNumber=57, createdTime=2020-05-15, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cd1840921e, moduleTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92cd1840921e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786996, encodeId=fdc81e869967a, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=NEJM： Pembrolizumab单抗治疗进行性多灶性白质脑病, objectType=article, longId=164082, objectId=88a016408258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88a016408258, replyNumber=0, likeNumber=75, createdTime=2020-03-26, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88a016408258, moduleTitle=NEJM： Pembrolizumab单抗治疗进行性多灶性白质脑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88a016408258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786995, encodeId=41031e86995a2, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Blood：ASCT后采用Pembrolizumab巩固治疗可提高经典霍奇金淋巴瘤患者的预后, objectType=article, longId=163988, objectId=48b6163988a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48b6163988a4, replyNumber=0, likeNumber=59, createdTime=2019-10-25, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48b6163988a4, moduleTitle=Blood：ASCT后采用Pembrolizumab巩固治疗可提高经典霍奇金淋巴瘤患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48b6163988a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786994, encodeId=6acd1e8699418, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Lancet：Pembrolizumab可单药治疗低PD-L1 TPS的晚期非小细胞肺癌, objectType=article, longId=163734, objectId=df88163e345a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df88163e345a, replyNumber=0, likeNumber=68, createdTime=2019-11-17, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df88163e345a, moduleTitle=Lancet：Pembrolizumab可单药治疗低PD-L1 TPS的晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df88163e345a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786992, encodeId=90ed1e8699248, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=EDP1503联合pembrolizumab治疗多种肿瘤的I/II临床试验正式开始, objectType=article, longId=159159, objectId=483d15915902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=483d15915902, replyNumber=0, likeNumber=78, createdTime=2020-01-09, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=483d15915902, moduleTitle=EDP1503联合pembrolizumab治疗多种肿瘤的I/II临床试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=483d15915902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786998, encodeId=b1441e8699891, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=ARCH PATHOL LAB MED：程序死亡配体-1表达阳性评分与Pembrolizumab治疗胃癌的临床应用, objectType=article, longId=165763, objectId=4f94165e63aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f94165e63aa, replyNumber=0, likeNumber=80, createdTime=2019-10-19, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f94165e63aa, moduleTitle=ARCH PATHOL LAB MED：程序死亡配体-1表达阳性评分与Pembrolizumab治疗胃癌的临床应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f94165e63aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786993, encodeId=cb851e86993af, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=KEYTRUDA（pembrolizumab）与Inlyta（阿西替尼）组合显著降低了晚期肾细胞癌患者的死亡风险, objectType=article, longId=160426, objectId=a9a11604268e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a11604268e, replyNumber=0, likeNumber=66, createdTime=2019-05-31, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a11604268e, moduleTitle=KEYTRUDA（pembrolizumab）与Inlyta（阿西替尼）组合显著降低了晚期肾细胞癌患者的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9a11604268e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786987, encodeId=b82f1e8698710, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Pembrolizumab和聚乙二醇化干扰素α-2b在晚期黑色素瘤中的Ib / II期研究, objectType=article, longId=151983, objectId=6e2e151983a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e2e151983a4, replyNumber=0, likeNumber=92, createdTime=2019-08-01, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e2e151983a4, moduleTitle=JCO：Pembrolizumab和聚乙二醇化干扰素α-2b在晚期黑色素瘤中的Ib / II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e2e151983a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786989, encodeId=e5171e86989f3, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Pembrolizumab新辅助治疗肌层浸润性膀胱癌, objectType=article, longId=152424, objectId=e34715242443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e34715242443, replyNumber=0, likeNumber=66, createdTime=2019-01-03, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e34715242443, moduleTitle=JCO：Pembrolizumab新辅助治疗肌层浸润性膀胱癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e34715242443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786990, encodeId=aea51e869904f, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床, objectType=article, longId=153201, objectId=ee2f15320164, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee2f15320164, replyNumber=0, likeNumber=68, createdTime=2019-01-13, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee2f15320164, moduleTitle=JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee2f15320164)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786986, encodeId=823b1e8698634, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤, objectType=article, longId=150031, objectId=8f8f1500318b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8f1500318b, replyNumber=0, likeNumber=83, createdTime=2018-12-30, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8f1500318b, moduleTitle=JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f8f1500318b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786997, encodeId=961c1e86997ce, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=II期研究的更新数据以评估DPX-Survivac与Pembrolizumab联合治疗DLBCL的有效性, objectType=article, longId=165418, objectId=11561654182e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11561654182e, replyNumber=0, likeNumber=67, createdTime=2020-03-04, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11561654182e, moduleTitle=II期研究的更新数据以评估DPX-Survivac与Pembrolizumab联合治疗DLBCL的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11561654182e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786979, encodeId=70db1e8697924, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J Clin Oncol：pembrolizumab提高癌症患者生活质量, objectType=article, longId=133890, objectId=1adc13389035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1adc13389035, replyNumber=0, likeNumber=63, createdTime=2018-07-22, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1adc13389035, moduleTitle=J Clin Oncol：pembrolizumab提高癌症患者生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1adc13389035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786991, encodeId=942a1e869919d, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Lancet：Pembrolizumab用于晚期头颈癌效果显著, objectType=article, longId=155053, objectId=4fdc15505384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fdc15505384, replyNumber=0, likeNumber=65, createdTime=2019-09-18, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fdc15505384, moduleTitle=Lancet：Pembrolizumab用于晚期头颈癌效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fdc15505384)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Pembro

2020-05-29

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定

2020-04-22

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Hyleukin-7（NT-I7）联合Pembrolizumab治疗复发难治晚期实体瘤：美国FDA已批准IND申请

2020-03-08

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Pembrolizumab治疗难治性，微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究：KEYNOTE-164

2020-10-16

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

ASCO：真实世界中pembrolizumab单抗对NSCLC效果如何联用？

2020-05-10

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Lancet：Pembrolizumab治疗复发或转移性头颈部鳞状细胞癌

2019-11-25

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关

2021-01-11

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗

2020-05-15

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

NEJM： Pembrolizumab单抗治疗进行性多灶性白质脑病

2020-03-26

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Blood：ASCT后采用Pembrolizumab巩固治疗可提高经典霍奇金淋巴瘤患者的预后

2019-10-25

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Lancet：Pembrolizumab可单药治疗低PD-L1 TPS的晚期非小细胞肺癌

2019-11-17

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

EDP1503联合pembrolizumab治疗多种肿瘤的I/II临床试验正式开始

2020-01-09

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

ARCH PATHOL LAB MED：程序死亡配体-1表达阳性评分与Pembrolizumab治疗胃癌的临床应用

2019-10-19

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

KEYTRUDA（pembrolizumab）与Inlyta（阿西替尼）组合显著降低了晚期肾细胞癌患者的死亡风险

2019-05-31

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Pembrolizumab和聚乙二醇化干扰素α-2b在晚期黑色素瘤中的Ib / II期研究

2019-08-01

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Pembrolizumab新辅助治疗肌层浸润性膀胱癌

2019-01-03

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床

2019-01-13

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤

2018-12-30

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

II期研究的更新数据以评估DPX-Survivac与Pembrolizumab联合治疗DLBCL的有效性

2020-03-04

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J Clin Oncol：pembrolizumab提高癌症患者生活质量

2018-07-22

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Lancet：Pembrolizumab用于晚期头颈癌效果显著

2019-09-18

科室
- - 订阅+
  - 更多科室
工具
服务